Trial Profile
Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms LOTS
- Sponsors Genzyme Corporation
- 28 Apr 2017 Results assessing long-term efficacy of alglucosidase alfa in late-onset pompe disease patients from LOTS study, its open-label extension and Pompe Registry, presented at the 69th Annual Meeting of the American Academy of Neurology
- 19 May 2014 New trial record
- 27 Mar 2006 Status has been changed to active, no longer recruiting.